AR055603A1 - Vacuna contra la infeccion por virus del dengue - Google Patents
Vacuna contra la infeccion por virus del dengueInfo
- Publication number
- AR055603A1 AR055603A1 ARP060103502A ARP060103502A AR055603A1 AR 055603 A1 AR055603 A1 AR 055603A1 AR P060103502 A ARP060103502 A AR P060103502A AR P060103502 A ARP060103502 A AR P060103502A AR 055603 A1 AR055603 A1 AR 055603A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine
- yellow fever
- chimeric flavivirus
- dengue viruses
- virus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000710829 Dengue virus group Species 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 241000710831 Flavivirus Species 0.000 abstract 3
- 241000710772 Yellow fever virus Species 0.000 abstract 2
- 229940051021 yellow-fever virus Drugs 0.000 abstract 2
- 206010012310 Dengue fever Diseases 0.000 abstract 1
- 241000725619 Dengue virus Species 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract 1
- 229940124926 Yellow fever virus vaccine Drugs 0.000 abstract 1
- 208000025729 dengue disease Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960001515 yellow fever vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70703805P | 2005-08-10 | 2005-08-10 | |
| US71944805P | 2005-09-22 | 2005-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055603A1 true AR055603A1 (es) | 2007-08-29 |
Family
ID=37758084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103502A AR055603A1 (es) | 2005-08-10 | 2006-08-10 | Vacuna contra la infeccion por virus del dengue |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080193477A1 (https=) |
| EP (1) | EP1924280A4 (https=) |
| JP (1) | JP5227172B2 (https=) |
| AR (1) | AR055603A1 (https=) |
| AU (1) | AU2006280144B2 (https=) |
| BR (1) | BRPI0614265A2 (https=) |
| CA (1) | CA2618783A1 (https=) |
| IL (1) | IL189329A (https=) |
| MY (1) | MY151051A (https=) |
| NO (1) | NO20081127L (https=) |
| TW (1) | TW200740458A (https=) |
| WO (1) | WO2007021672A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| AU2010256845B2 (en) * | 2009-06-01 | 2016-09-22 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| US9821050B2 (en) | 2012-04-02 | 2017-11-21 | The University Of North Carolina At Chapel Hill | Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions |
| AU2013295016A1 (en) | 2012-07-24 | 2015-01-29 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| SG10201912291YA (en) | 2012-07-24 | 2020-02-27 | Sanofi Pasteur | Vaccine compositions |
| BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
| US9878031B2 (en) | 2012-12-14 | 2018-01-30 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| EP2968516B1 (en) | 2013-03-15 | 2022-01-12 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
| KR20160119806A (ko) * | 2014-02-11 | 2016-10-14 | 메사추세츠 인스티튜트 오브 테크놀로지 | 신규한 온전한 범위의 항-뎅기 항체 |
| DK3197487T3 (da) | 2014-09-26 | 2022-09-05 | Seqirus Uk Ltd | Vaccination af immunsvækkede individer |
| GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
| WO2018183429A1 (en) | 2017-03-30 | 2018-10-04 | Merck Sharp & Dohme Corp. | Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids |
| WO2019069130A1 (en) | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE |
| EP3846849A1 (en) | 2018-09-05 | 2021-07-14 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| BR112022001476A2 (pt) | 2019-08-16 | 2023-10-03 | Takeda Vaccines Inc | Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit |
| BR112022015710A2 (pt) | 2020-02-27 | 2022-09-27 | Takeda Vaccines Inc | Método para remover dna de célula hospedeira a partir da preparação de vírus |
| WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| US20250177511A1 (en) | 2022-02-15 | 2025-06-05 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| US20250342705A1 (en) | 2022-05-04 | 2025-11-06 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| WO2024108087A1 (en) | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| EP4626574A1 (en) | 2022-11-29 | 2025-10-08 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6676936B1 (en) * | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| US7192593B2 (en) * | 1997-05-23 | 2007-03-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| AU1813901A (en) * | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
| US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
| US6966281B1 (en) * | 2004-05-05 | 2005-11-22 | Hale James R | Internal combustion device and methods of use |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-08-09 JP JP2008526124A patent/JP5227172B2/ja not_active Expired - Fee Related
- 2006-08-09 EP EP06800943A patent/EP1924280A4/en not_active Ceased
- 2006-08-09 WO PCT/US2006/030846 patent/WO2007021672A2/en not_active Ceased
- 2006-08-09 AU AU2006280144A patent/AU2006280144B2/en not_active Ceased
- 2006-08-09 CA CA002618783A patent/CA2618783A1/en not_active Abandoned
- 2006-08-09 BR BRPI0614265-6A patent/BRPI0614265A2/pt not_active Application Discontinuation
- 2006-08-09 US US12/063,365 patent/US20080193477A1/en not_active Abandoned
- 2006-08-10 TW TW095129386A patent/TW200740458A/zh unknown
- 2006-08-10 MY MYPI20063881 patent/MY151051A/en unknown
- 2006-08-10 AR ARP060103502A patent/AR055603A1/es unknown
-
2008
- 2008-02-06 IL IL189329A patent/IL189329A/en not_active IP Right Cessation
- 2008-03-04 NO NO20081127A patent/NO20081127L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1924280A4 (en) | 2008-12-10 |
| IL189329A0 (en) | 2008-06-05 |
| EP1924280A2 (en) | 2008-05-28 |
| MY151051A (en) | 2014-03-31 |
| TW200740458A (en) | 2007-11-01 |
| WO2007021672A2 (en) | 2007-02-22 |
| JP2009504654A (ja) | 2009-02-05 |
| WO2007021672A3 (en) | 2007-11-22 |
| US20080193477A1 (en) | 2008-08-14 |
| BRPI0614265A2 (pt) | 2011-03-22 |
| JP5227172B2 (ja) | 2013-07-03 |
| NO20081127L (no) | 2008-05-07 |
| AU2006280144B2 (en) | 2012-06-14 |
| IL189329A (en) | 2015-07-30 |
| AU2006280144A1 (en) | 2007-02-22 |
| CA2618783A1 (en) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055603A1 (es) | Vacuna contra la infeccion por virus del dengue | |
| PH12019500289A1 (en) | Vaccines directed against a human enteroviruses | |
| MX2018007860A (es) | Vacunas recombinantes contra el zika. | |
| EA201490654A1 (ru) | Новые ингибиторы вирусной репликации | |
| ECSP14005678A (es) | Composiciones y métodos para tratar el virus de la hepatitis c | |
| CL2009002207A1 (es) | Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c. | |
| JP2009504654A5 (https=) | ||
| BR112012000287B8 (pt) | composição farmacêutica para um inibidor de protease viral de hepatite c | |
| CO6160335A2 (es) | Vacuna | |
| AR061887A1 (es) | Una composicion de vacuna contra el dengue | |
| MX383416B (es) | Nueva vacuna contra la influenza porcina. | |
| Newcomer et al. | Approved and experimental countermeasures against pestiviral diseases: bovine viral diarrhea, classical swine fever and border disease | |
| NZ597000A (en) | Compositions and methods for administration of vaccines against dengue virus | |
| CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
| AR093185A1 (es) | Virus prrs (sindrome reproductivo y respiratorio porcino) que induce al interferon tipo i en celulas susceptibles | |
| AR041964A1 (es) | Vacuna de vhc que comprende un polinucleotido | |
| CO2022017989A2 (es) | Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas | |
| Valiakos et al. | West Nile virus: Basic principles, replication mechanism, immune response and important genetic determinants of virulence | |
| MX2023007229A (es) | Constructo de arn. | |
| CL2013002829A1 (es) | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. | |
| UY38933A (es) | Vacuna de partículas tipo virus del chicunguña y métodos para su uso | |
| AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
| Muqadas et al. | Rift valley fever | |
| PH12022550261A1 (en) | Methods for preventing dengue and hepatitis a | |
| WO2011121162A1 (es) | Uso del ácido valproico como antiviral contra virus con envoltura |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |